The UK is at risk of losing its world-leading life sciences status due to investment being captured elsewhere on the international stage, according to trade body Association of the British ...

The UK pharmaceutical intermediate market is poised for steady growth, with an estimated value of USD 1,156.0 million in 2025 ...

I invest for long-term total return, focusing on high-quality, dividend-paying industry leaders with strong financials and consistent performance. Despite current headwinds like tariffs and patent ...

LONDON, March 20 (Reuters) - The pharmaceutical industry on Thursday blasted the UK government's levy that aims to curb the national health system's drugs bill, arguing it is unsustainable and is ...

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the Association of the British Pharmaceutical Industry (ABPI). As one of the two ...

The United States and Britain announced a deal on Monday to securezero tariffs on British pharmaceutical products and medical ...

New government legislation is needed to ensure full transparency of payments made by pharmaceutical companies to UK healthcare professionals and organisations to protect patient safety and public ...

The Trump administration reached a deal with the UK to allow tariff-free imports of pharmaceutical products in exchange for a significant reduction in rebates drugmakers pay to Britain’s National ...

The government has agreed to a major deal with the US that will see the UK become the only country to secure zero import tariffs on pharma ...

Pharma and Biopharma is a trillion-dollar industry providing ample career opportunities for laboratory scientists and entrepreneurs. Join Principal Consultant Michael W. Dong of MWD Consulting as he ...